Boehringer Ingelheim Program on Track
In May 2015 Boehringer acquired the Pharmaxis investigational drug PXS-4728A to develop initially as a treatment for non-alcoholic steatohepatitis (NASH). During the March 2016 quarter Boehringer provided a program update confirming the planned timing for the commencement of a phase 2 clinical trial as the first quarter of 2017. The commencement of a phase 2 trial triggers the payment of a development milestone to Pharmaxis of approximately A$25 million.
Latest news on NASH
A silent liver disease epidemic As nonalcoholic steatohepatitis, or NASH, stealthily becomes a leading cause of liver transplants, drug companies are racing to develop treatments. , Chemical & Engineering News, October 3, 2016
Pharmaxis Announces Russian Approval For Bronchitol - Largest Market Accessed to Date
Pharmaxis is pleased to announce its drug Bronchitol® has been approved for marketing in Russia for the treatment of both paediatric and adult cystic fibrosis (CF) patients. Russia is the largest market accessed to date for Bronchitol.
In a landmark decision Bronchitol today became the first medicine to be processed under new Russian laws to provide patients access to innovative medicines.The new orphan drug legislation was announced by the Russian Ministry of Health in January 2016, and Bronchitol was designated as an orphan drug the following month.
There are approximately 7,400 CF patients on the Russian Cystic Fibrosis Registry, but it is estimated there are between 3,000 and 6,000 CF patients living in rural regions not currently included on the registry. Last year the Russian market for CF drugs to deal with mucus clearance was approximately US$29 million. The first Russian sales of Bronchitol are expected before the end of 2016.
Research Collaboration with Woolcock Institute on Novel Cystic Fibrosis Therapy
Pharmaceutical research company Pharmaxis (ASX: PXS) is pleased to announce a research collaboration with Sydney’s prestigious Woolcock Institute of Medical Research to develop a novel inhalation therapy for the treatment of cystic fibrosis (CF).
The National Health and Medical Research Council (NHMRC) has awarded a research grant of $421,545 for development and testing of the Orbital® Inhaler with a dry powder formulation of the antibiotic tobramycin. The Orbital inhaler is a Pharmaxis invention which has been designed to deliver high-doses of dry powder drugs to the lungs in a more effective and convenient manner than existing technology.
Stopping Scars Before They Form
Pharmaxis is collaborating on a potential new scar treatment for burns, keloids and Dupuytren contracture. Early stage research from a group including The University of Western Australia, Fiona Wood Foundation, Royal Perth Hospital Burns Unit and Pharmaxis has been presented at the prestigious American Chemical Society meeting in Philadelphia.